PrEP and the HIV Workforce: Expanding the Knowledge Network

Release date: November 1, 2019

Expiration date: November 1, 2020

Estimated time to complete activity: 45 minutes

This activity is jointly provided by the Postgraduate Institute for Medicine and the American Academy of HIV Medicine.

This activity is supported by independent educational grants from Gilead Sciences, Inc.

aahivm logo

Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, and registered nurses; other healthcare providers, such as nutritionists, social workers, and case managers are also encouraged to attend.

Statement of Need/Program Overview
AAHIVM can utilize its vast network of HIV Specialist HCPs across the country to reach clinics, providers (particularly general/family practice HCPs) and patients who need understanding and training regarding the effectiveness and availability of PrEP, when and how to screen for HIV disease (assess for risk) and how best to refer/link to care when additional specialization is required for treatment.

Educational Objectives
After completing this activity, the participant should be better able to:
  • Identify populations/patients at risk for HIV acquisition
  • Recite evidence of the need for PrEP services
  • Identify the components of PrEP
  • Identify the role of the pharmacist in using PrEP
  • Discuss the issue of adolescent PrEP use
  • Identify patients who require PEP and n PEP (post-exposure) and offer prophylactic treatment according to guidelines.
  • Identify and implement the needs, approaches, cultural competencies and CDC guidelines specific to offering PrEP in the Black Men Who Have Sex With Men (MSM) and Women of Color patient populations.

Jonathan Appelbaum, MD, FACP, AAHIVS
Chair, Department of Clinical Sciences
Educational Director of Internal Medicine
Florida State University College of Medicine

Robert Wallace, MD, AAHIVS
Chief Medical Officer, Love the Golden Rule, Inc.
Saint Petersburg, Florida

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and American Academy of HIV Medicine.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0809-9999-17-938-L02-P)

Type of Activity: Application

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. (If applicable for APRNs) Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a positionto control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Robert Wallace, MD, AAHIVS: Nothing to disclose

Bruce Packett (AAHIVM): Nothing to disclose

Kaitlyn Rush (AAHIVM): Nothing to disclose

Amber McCracken (AAIHVM): Nothing to disclose

Jonathan Appelbaum, MD, FACP, AAHIVS: Fees for Non-CME/CE Services: ViiV Healthcare, Merck

The PIM planners and managers have nothing to disclose.

Method of Participation and Request for Credit:
There are no fees for participating and receiving CME/CE credit for this activity. During the period November 1, 2019 through November 1, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 13467. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service.

Type of activity: Internet

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

In this activity the faculty do discuss the use of investigational antiretroviral agents and treatment regimens that are not approved by treatment guidelines.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**Please note: The following additional slides reflect newly updated data on PrEP. Download PDF